Amylon Therapeutics
Leiden
About Amylon Therapeutics
Amylon Therapeutics is a biotechnology company that uses RNA Modulation Technology to target rare genetic disorders of the central nervous system (CNS). Our mission is to deliver on the potential of our technology by developing life-changing therapeutic solutions for patients with serious unmet medical need. We have high ambitions and want to change the way the world looks at neurological disorders. The enormous burden these diseases put on patients and their loved ones is unacceptable and something we strive to change every day. We believe that every patient deserves the hope for a brighter future. Our vision is to build a sustainable drug development platform in which the whole is bigger than the sum of its parts. This will allow us to focus on CNS diseases large and small and hopefully leave no patient untreated.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $349.4K
- Funding stage: Seed
- Last round: Seed (Nov 2017)
- Website: amylontx.com
- Phone: 020-4044707
Industries & Categories
Biotechnology, Genetics, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amylon-therapeutics-203413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.